Search
Now showing items 11-20 of 7912
Evaluation of ceftiofur-PHBV microparticles in rats
(Dove Medical Press Ltd., 2014)
Emerging strategies on in silico drug development against COVID-19: challenges and opportunities
The importance of coronaviruses as human pathogen has been highlighted by the recent
outbreak of SARS-CoV-2 leading to the search of suitable drugs to overcome respiratory
infections caused by the virus. Due to the lack ...
Cholinesterase inhibitors for Alzheimer's disease: Multitargeting strategy based on anti-Alzheimer's drugs repositioning
(Bentham Science Publishers, 2019)
Folate biosynthesis pathway: mechanisms and insights into drug design for infectious diseases
(Future Sci Ltd, 2018-04-01)
Folate pathway is a key target for the development of new drugs against infectious diseases since the discovery of sulfa drugs and trimethoprim. The knowledge about this pathway has increased in the last years and the ...
Molecular modeling databases: A new way in the search of protein targets for drug development
(2007-01-01)
DBMODELING is a relational database of annotated comparative protein structure models and their metabolic, pathway characterization. It is focused on enzymes identified in the genomes of Mycobacterium tuberculosis and ...
Molecular modeling databases: A new way in the search of protein targets for drug development
(2007-01-01)
DBMODELING is a relational database of annotated comparative protein structure models and their metabolic, pathway characterization. It is focused on enzymes identified in the genomes of Mycobacterium tuberculosis and ...
Comparison of impurity profiles of lipiblock® vs. orlistat using HPLC and LC-MS/MS
(2012-04-30)
Comparative HPLC-UV and LC-MS/MS studies of impurity profiles of a reference sample (Xenical®, F. Hoffmann-La Roche Ltd., Switzerland) vs. generic (Lipiblock®, EMS-Sigma Pharma, a generic drug) were carried out with ethanol ...
Comparison of impurity profiles of lipiblock® vs. orlistat using HPLC and LC-MS/MS
(2012-04-30)
Comparative HPLC-UV and LC-MS/MS studies of impurity profiles of a reference sample (Xenical®, F. Hoffmann-La Roche Ltd., Switzerland) vs. generic (Lipiblock®, EMS-Sigma Pharma, a generic drug) were carried out with ethanol ...